Division of Novartis AG
Latest From Sandoz Canada
Health Canada asks ranitidine H2 blocker firms to halt sales until it gathers more information on NDMA contamination, which may form due to the drug’s instability. At least one marketer, Sandoz, also is recalling its ranitidine products in both Canada and US.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced in late July-September 2014.
Agency argues it can’t recall generic versions of Precedex as part of Hospira’s patent suit.
- Generic Drugs
- Therapeutic Areas
- Neurology, Nervous System
- Sabex 2002 Inc.
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Michel Robidoux, Pres.
Jacquelin Gagnon, VP, Sales & Mktg.
Marc Beaudoin, VP, Strategy & Bus. Dev.
Len Arsenault , VP, Scientific Affairs
Martin Fournier, VP, Fin. & IT
- Contact Info
Phone: (450) 641-4903
145 Jules Leger
Boucherville, J4B 7K8
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.